Palmetto Peptides Guide to the Research Peptide Semax
Research Use Only Disclaimer: All content on this page is intended exclusively for licensed researchers, academics, and scientific professionals conducting preclinical studies in approved laboratory settings. Semax is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. Nothing on this page constitutes medical advice, and this content should not be interpreted as a recommendation or endorsement of any particular use. Researchers must comply with all applicable federal, state, and institutional regulations.
Palmetto Peptides Guide to the Research Peptide Semax
Last Updated: April 13, 2026 | Author: Palmetto Peptides Research Team
Semax is one of the most studied synthetic peptides in preclinical neuroscience, with a published research record spanning more than three decades. In animal model studies, it has been associated with meaningful upregulation of brain-derived neurotrophic factor (BDNF), neuroprotection in ischemia models, and broad transcriptomic changes in brain tissue. For researchers working in neurological disease modeling, cognitive function studies, or neurotrophic factor research, Semax represents a well-characterized tool peptide with a robust supporting literature.
This guide consolidates what the peer-reviewed preclinical research says about Semax — its structure, its documented mechanisms in animal models, laboratory handling best practices, how it compares to related peptides, and how to evaluate suppliers for research-grade material. Everything here is written for licensed laboratory researchers and is strictly informational.
What Is the Semax Research Peptide?
Semax is a synthetic heptapeptide — meaning it is composed of seven amino acids — derived from a fragment of adrenocorticotropic hormone (ACTH). Specifically, it corresponds to the ACTH(4-10) sequence with a C-terminal Pro-Gly-Pro extension added by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences.
Its amino acid sequence is: Met-Glu-His-Phe-Pro-Gly-Pro
In plain terms: ACTH is a hormone the body naturally produces to regulate stress responses and adrenal function. Scientists identified a short region of ACTH — amino acids 4 through 10 — that appeared to have neurological activity on its own, separate from ACTH's hormonal functions. Semax was built by isolating that region and extending it slightly to improve stability. The result is a peptide that can be studied in isolation from the broader hormonal effects of ACTH itself.
Semax was first developed in Russia during the 1980s and has since been the subject of over 100 peer-reviewed publications in preclinical settings, primarily using rodent models. In the United States, it is available exclusively as a research chemical for use in licensed laboratory settings and has not received FDA approval for any therapeutic application.
View Semax at Palmetto Peptides →
Molecular Structure and Key Properties
| Property | Detail |
|---|---|
| Peptide sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular formula | C₃₇H₅₁N₉O₁₀S |
| Molecular weight | Approximately 813.9 g/mol |
| Origin | Derived from ACTH(4-10) fragment |
| Development | Institute of Molecular Genetics, Russian Academy of Sciences |
| Primary research category | Neuropeptide / Nootropic peptide (preclinical) |
| Administration routes studied | Intranasal (IN), subcutaneous (SC), intraperitoneal (IP) in animal models |
| Physical form (research grade) | Lyophilized white powder |
| Storage (lyophilized) | -20°C, protected from moisture and light |
| Storage (reconstituted) | 4°C, use within 28-30 days |
The Pro-Gly-Pro extension at the C-terminus is significant. It confers resistance to enzymatic cleavage that would otherwise break down the peptide rapidly in biological media — a practical advantage for maintaining activity duration in animal model experiments.
How Semax Works: Mechanism of Action in Preclinical Models
Understanding how Semax produces its documented effects in animal models requires a brief overview of the systems it interacts with. The following reflects findings from peer-reviewed preclinical studies only.
BDNF Upregulation
The most consistently documented effect of Semax in rodent studies is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor, TrkB.
BDNF is a protein in the brain that supports the survival and growth of neurons (nerve cells), promotes the formation of new synaptic connections (synapses are the junctions between neurons where communication happens), and plays a major role in learning and memory-related processes in animal models. When BDNF expression increases in brain tissue, it signals that neurons are receiving growth support.
In studies using rat models, Semax administration has been shown to significantly increase BDNF mRNA levels in the hippocampus and frontal cortex — two brain regions closely associated with memory function and executive processing in mammalian models. Some research has documented BDNF increases of two to four times baseline in these regions following Semax administration in rodent experiments.
For a detailed breakdown of this mechanism, see our supporting article: Semax and BDNF Expression: What Preclinical Animal Model Research Reveals →
Melanocortin Receptor Interaction
Semax, as a derivative of the ACTH(4-10) fragment, interacts with melanocortin receptors — specifically MC4R and potentially MC3R. These receptors are distributed throughout the central nervous system in rodent models and are implicated in a range of neurological processes including energy regulation, stress response, and inflammatory signaling.
Gene Expression Modulation
Microarray studies in rat brain tissue have identified broad transcriptomic changes following Semax administration, spanning three major gene categories: neurotrophic and synaptic plasticity genes, neuroinflammatory genes (particularly those related to cytokine signaling), and vascular remodeling genes. The Medvedeva et al. (2014) study in the Journal of Neurochemistry remains one of the most cited works documenting this breadth of effect.
For full details on this mechanism: Semax Research Peptide Effects on Gene Expression in Rat Brain Preclinical Studies →
Dopamine and Serotonin System Activity
Several rodent studies have reported that Semax influences dopaminergic and serotonergic neurotransmitter activity in brain tissue. In layman's terms: these are chemical messenger systems that regulate mood, motivation, attention, and other behavioral states in mammals. Changes in these systems have been observed in behavioral outcome measures in animal models following Semax administration, though the precise receptor-level mechanisms remain an active area of preclinical investigation.
Semax in Neuroprotection Research: What Animal Models Show
One of the most extensively published areas of Semax research involves its effects in ischemia models — laboratory simulations of stroke-like conditions in animals.
The most common model used is middle cerebral artery occlusion (MCAO), in which blood flow to a region of a rat's brain is temporarily restricted, then restored. This models the kind of brain injury that occurs in ischemic stroke. Researchers then measure outcomes including infarct volume (the size of the damaged area), neurological deficit scores (assessments of motor and behavioral function), and cellular survival markers.
Summary of Neuroprotection Findings in MCAO Models
| Outcome Measure | Typical Finding in Semax-Treated Animals |
|---|---|
| Infarct volume | Reduction reported in multiple studies vs. control |
| Neurological deficit scores | Improvement documented in treated groups |
| BDNF levels in ischemic tissue | Significant upregulation vs. saline control |
| Anti-apoptotic markers | Increased expression in treated animals |
| Inflammatory cytokine activity | Modulated (reduced pro-inflammatory signaling) |
The proposed mechanism unfolds in stages: Semax first activates melanocortin receptors, which triggers intracellular signaling cascades that upregulate BDNF gene expression. Elevated BDNF then activates TrkB receptors on neurons, initiating neuroprotective pathways that reduce apoptosis (programmed cell death) and support neuronal survival in the ischemic region. Simultaneously, Semax-associated modulation of inflammatory gene expression appears to dampen the secondary neuroinflammatory response that typically extends injury in ischemia models.
For a full breakdown of this cascade: Mechanism of Action of the Semax Research Peptide in Ischemia Animal Models →
And for a broader summary of neuroprotection findings across studies: Semax Research Peptide in Neuroprotection Studies: Key Findings from Animal Models →
Semax and Cognitive Function in Animal Models
Beyond neuroprotection, Semax has been studied in the context of cognitive function using standard preclinical behavioral assays. The most commonly used tests include:
Morris Water Maze — Rats are placed in a pool and must locate a submerged platform using spatial memory cues. Performance is measured by time to find the platform and path efficiency. Semax-treated animals have shown reduced latency (faster platform location) and more direct swim paths compared to controls in multiple studies.
Novel Object Recognition (NOR) — Animals are exposed to familiar and unfamiliar objects. Preference for the novel object reflects intact recognition memory. Semax-treated groups have demonstrated higher novel object preference in some rodent studies.
Passive Avoidance — Animals are conditioned to avoid an area associated with a mild aversive stimulus. Retention of this learned avoidance over time is a measure of aversive memory consolidation. Semax-treated animals have shown enhanced retention in passive avoidance paradigms in multiple publications.
The mechanistic link between these behavioral findings and Semax-associated BDNF upregulation is an active area of investigation. Researchers hypothesize that elevated BDNF in hippocampal and cortical tissue supports synaptic plasticity processes (the cellular basis of learning in animal models), though causality has not been definitively established.
For the most current review of this research area: Latest Preclinical Findings on Semax Research Peptide in Cognitive Function Animal Models (2026 Review) →
Semax vs. Related Research Peptides
Researchers selecting a peptide for preclinical study often compare Semax to closely related compounds. Here is a brief orientation to the most common comparisons.
Semax vs. Selank
Selank is a synthetic analog of tuftsin — a naturally occurring immunomodulatory peptide. Like Semax, Selank was developed in Russia and has a substantial preclinical literature. But the two peptides target different systems and occupy distinct research niches.
| Feature | Semax | Selank |
|---|---|---|
| Structural origin | ACTH(4-10) fragment | Tuftsin analog |
| Primary research focus | BDNF upregulation, neuroprotection | Anxiolytic-like behavior, immune modulation |
| Key receptor interaction | Melanocortin receptors (MC3R/MC4R) | Tuftsin receptors, enkephalinase inhibition |
| Primary animal models | MCAO, spatial memory, gene expression | Elevated plus maze, open field, immune assays |
| Predominant CNS region studied | Hippocampus, frontal cortex | Amygdala, limbic system |
These peptides are not interchangeable in experimental design. The choice depends entirely on the research question.
For a detailed head-to-head comparison: Semax Research Peptide vs Selank: Key Differences in Preclinical Neuroscience Studies →
If your lab works with Selank, you can view it here: Selank Research Peptide at Palmetto Peptides →
Semax vs. N-Acetyl Semax
N-Acetyl Semax is a structurally modified version of standard Semax in which an acetyl group is attached to the peptide's N-terminus (the beginning of the amino acid chain). This modification improves proteolytic stability — meaning the modified peptide resists enzymatic breakdown more effectively.
In practical laboratory terms: if your experimental model involves biological matrices where peptide degradation is a concern, or if you are designing a longer-duration protocol, N-Acetyl Semax may offer a more stable research tool. Standard Semax remains the better-characterized compound in the existing literature, which may matter for researchers building on prior published protocols.
For the full structural and application comparison: N-Acetyl Semax vs Standard Semax Research Peptide: Structural and Lab Application Differences →
View N-Acetyl Semax at Palmetto Peptides: N-Acetyl Semax →
Laboratory Handling: Storage, Reconstitution, and Administration
Research-grade Semax is supplied as a lyophilized (freeze-dried) powder. Proper handling is essential for maintaining peptide integrity and ensuring experimental reproducibility.
Storage of Lyophilized Semax
Lyophilized Semax should be stored at -20°C in a sealed, desiccated container, away from light and moisture. Under these conditions, the peptide retains stability for 24 months or longer (manufacturer CoA specifications vary — confirm with your supplier).
Reconstitution Protocol
To reconstitute Semax for use in laboratory experiments, researchers typically use bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). This is the standard reconstitution vehicle for research peptides and supports a 28-to-30-day refrigerated shelf life post-reconstitution.
General reconstitution steps used in preclinical research: 1. Allow the lyophilized vial to reach room temperature before opening (prevents condensation contamination). 2. Add bacteriostatic water slowly down the side of the vial, not directly onto the lyophilized cake. 3. Gently swirl — do not vortex or shake aggressively, as this can degrade peptide structure. 4. Allow the solution to settle and clear before use. 5. Aliquot immediately into single-use volumes to prevent repeated freeze-thaw cycles.
For a complete handling and storage protocol reference: Best Practices for Storing and Handling Semax Research Peptide in Laboratory Settings →
Palmetto Peptides also carries bacteriostatic water for use in peptide reconstitution.
Administration Routes in Animal Model Research
The most common administration routes studied in the Semax literature are:
Intranasal (IN): The predominant route in published Semax research. Intranasal delivery allows peptides to bypass the blood-brain barrier — the protective filtering system that prevents most large molecules from crossing from the bloodstream into brain tissue — by traveling along olfactory nerve pathways directly to the CNS. In rat models, volumes of 5 to 20 µL per nostril are typical. This is the route used in the majority of BDNF and neuroprotection studies.
Subcutaneous (SC) and Intraperitoneal (IP): Used in some studies, particularly earlier Russian publications. These routes involve injection and do not benefit from the direct CNS pathway offered by intranasal delivery, but they remain valid research administration methods.
For a detailed protocol reference on intranasal administration in neuroscience research: Intranasal Administration of Semax Research Peptide in Neuroscience Laboratory Research →
Sourcing Research-Grade Semax: What to Look For
The quality of peptide research depends directly on the purity and integrity of the compounds used. Not all research peptide suppliers meet the same standards, and sourcing from a low-quality provider introduces variables that compromise experimental reproducibility.
Key Quality Indicators
Certificate of Analysis (CoA): Every batch of research-grade Semax should come with a batch-specific CoA from the manufacturer. A credible CoA includes HPLC purity data (look for 98%+ purity), mass spectrometry confirmation of molecular weight, endotoxin testing results, and residual solvent analysis. Be cautious of suppliers who cannot provide a current, batch-specific CoA upon request.
HPLC Purity: High-performance liquid chromatography (HPLC) separates the peptide from impurities and measures what percentage of the material is the target compound. For research applications, 98% or greater purity is the standard threshold. Material below this level introduces unknown variables.
Mass Spectrometry: Confirms the molecular identity of the peptide by measuring its mass-to-charge ratio. This is the definitive test that the correct peptide was synthesized.
Endotoxin Testing: Endotoxins are bacterial cell wall components that can cause severe inflammatory responses in animal models, confounding experimental results. Research-grade peptides should be tested for endotoxin content and fall below established limits (typically less than 1 EU/mg for standard research applications).
Synthesis Method: Reputable manufacturers use Fmoc solid-phase peptide synthesis (SPPS), which allows precise control over amino acid sequence assembly and produces consistent, high-purity output. This is the industry standard method.
For a complete supplier evaluation framework: How to Source High-Purity Semax for Research Labs: Supplier Evaluation Guide →
For background on the synthesis and manufacturing process itself: Semax Research Peptide Synthesis and Manufacturing: Insights for Laboratory Researchers →
And for purity standards and CoA interpretation: Purity Standards and Quality Testing for Research-Grade Semax Peptides →
Order Research-Grade Semax from Palmetto Peptides →
Related Peptides Available for Research
Researchers studying neuroprotection, neurotrophic factor modulation, or cognitive function in preclinical models often work with related compounds alongside Semax. Palmetto Peptides carries a full range of research-grade peptides relevant to these research areas.
| Peptide | Primary Research Focus | Link |
|---|---|---|
| Selank | Anxiolytic-like behavior, immune modulation | View → |
| N-Acetyl Semax | Enhanced stability variant of Semax | View → |
| BPC-157 | Tissue repair, angiogenesis models | View → |
| Ipamorelin | Growth hormone secretagogue research | View → |
| CJC-1295 | GHRH analog, GH secretion models | View → |
| NAD+ | Cellular energy metabolism, aging models | View → |
Regulatory and Legal Status
United States
Semax is not approved by the FDA for any therapeutic, dietary supplement, or clinical application. It is legally available in the United States as a research chemical for use in licensed laboratory and preclinical research settings. Marketing, selling, or distributing Semax for human consumption — or any representation that it is intended for human use — is not permitted under U.S. law.
Researchers purchasing Semax for legitimate preclinical study must comply with all applicable federal regulations, state laws, and institutional policies governing research chemical procurement and use. Animal studies must be conducted under IACUC-approved protocols.
International Status
Semax has a more complex international regulatory picture. It has been used in clinical settings in Russia and some Eastern European countries under different regulatory frameworks than exist in the United States. Researchers outside the U.S. should consult their national regulatory authority and institutional compliance office for guidance applicable to their jurisdiction.
Palmetto Peptides sells Semax exclusively as a research chemical. Our products are not intended for human or veterinary use, and we do not make therapeutic claims.
Peer-Reviewed Citations
The following peer-reviewed publications form the foundation of the preclinical Semax literature referenced throughout this guide. All are accessible via PubMed or their respective journal archives.
-
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
-
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228
-
Malinovskaya NA, Inozemtseva LS, Dolotov OV, et al. Semax and its analog Pro-Gly-Pro activate adaptive signaling pathways and reduce damage in the rat brain during ischemia and reperfusion. Journal of Neurochemistry. 2014;130(4):530-543.
-
Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine. 2013;4(4):223-252.
-
Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the acute period of hemispheric ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3):61-68.
-
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide semax affects rat brain neurotrophin content during local ischemia of the brain. Doklady Biological Sciences. 2006;411:392-394.
Frequently Asked Questions
What is Semax used for in research?
In preclinical laboratory settings, Semax has been studied primarily for its effects on BDNF expression, neuroprotection in ischemia models, cognitive function behavioral assays, and gene expression patterns in rodent brain tissue. It is used exclusively in licensed laboratory research and is not approved for human or veterinary use.
Is Semax safe?
The concept of safety is specific to context. Preclinical animal model studies have generally reported that Semax is well-tolerated in rodents at doses used in research protocols. No human safety data exists from FDA-regulated clinical trials, and Semax is not approved for human use. All research use must comply with institutional and regulatory requirements.
Does Semax cross the blood-brain barrier?
Preclinical research suggests that intranasal administration may allow Semax to bypass the blood-brain barrier by traveling along olfactory nerve pathways. Intravenous or subcutaneous routes have shown evidence of CNS activity in some studies, though the mechanism of CNS entry via these routes is less clearly characterized.
What is the research-grade purity standard for Semax?
Research-grade Semax should meet a minimum purity of 98% as measured by HPLC. Batch-specific certificates of analysis including mass spectrometry confirmation and endotoxin testing should be available from any credible supplier.
Can Semax be used with other peptides in research?
Some preclinical researchers have explored Semax in multi-peptide protocols. Any such use must follow institutional research protocols, IACUC approval where applicable, and ethical guidelines governing animal research. Palmetto Peptides provides Semax strictly for individual laboratory research use.
Summary
Semax is one of the most extensively studied synthetic neuropeptides in preclinical research, with a three-decade publication record centered on BDNF expression, neuroprotection in ischemia animal models, and cognitive behavioral outcomes in rodents. Its derivation from the ACTH(4-10) fragment gives it a distinct receptor interaction profile, its Pro-Gly-Pro extension improves in vivo stability, and the availability of modified forms like N-Acetyl Semax expands its research utility.
For preclinical researchers, Semax represents a well-characterized tool with a reproducible literature base. Experimental success depends on sourcing high-purity material with verified CoA documentation, following appropriate reconstitution and storage protocols, and designing studies that leverage the specific mechanisms documented in the published literature.
Palmetto Peptides supplies research-grade Semax at verified purity levels for licensed laboratory use. All products ship with batch-specific certificates of analysis.
View Semax and Order for Your Lab →
Author: Palmetto Peptides Research Team Last Updated: April 13, 2026
This content is produced for informational and educational purposes only. Palmetto Peptides does not sell products intended for human or veterinary use. All products are intended for licensed research use only. Nothing on this page constitutes medical advice or a recommendation for any particular application. Researchers are responsible for ensuring compliance with all applicable laws, regulations, and institutional policies.